Depression treatment may need to target cellular powerhouses, not just neurotransmitters. This emerging paradigm recognizes that brain immune cells called microglia undergo fundamental metabolic changes that could perpetuate depressive episodes through inflammatory cascades. The research reveals that microglia in depression switch their energy production systems, alternating between pro-inflammatory and anti-inflammatory states. This metabolic flexibility appears governed by mitochondrial function, with these cellular power plants orchestrating whether immune cells fuel brain inflammation or promote healing. When microglia shift toward inflammatory metabolism, they release cytokines that disrupt normal brain chemistry and may sustain depressive symptoms. The mitochondrial control of this process involves complex signaling pathways that determine whether microglia consume glucose through glycolysis (promoting inflammation) or rely on oxidative phosphorylation (supporting resolution). This metabolic reprogramming represents a sophisticated cellular decision-making system that could explain why depression often involves both inflammatory activation and impaired cellular energy production. The implications extend beyond traditional antidepressant approaches focused on serotonin or dopamine. Therapeutic strategies targeting microglial metabolism could address the inflammatory component of depression while simultaneously improving cellular energy efficiency. This dual approach might prove especially valuable for treatment-resistant cases where conventional medications fail. However, translating these cellular insights into clinical interventions remains challenging, requiring precise understanding of how to selectively modulate microglial metabolism without disrupting essential immune functions. The complexity of these metabolic networks suggests that personalized approaches based on individual inflammatory profiles may become necessary.